XML 77 R65.htm IDEA: XBRL DOCUMENT v3.25.3
Debt - Liability for Sale of Future Royalties (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2025
USD ($)
Debt Disclosure [Abstract]  
Beginning balance $ 2,081,776
Less: Non-cash royalty revenue payable to Royalty Pharma (149,160)
Plus: non-cash interest expense recognized 149,305
Ending balance $ 2,081,921
Effective interest rate of the liability component 9.30%